<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37001813</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2090-1224</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of advanced research</Title><ISOAbbreviation>J Adv Res</ISOAbbreviation></Journal><ArticleTitle>Advances in anti-EV-A71 drug development research.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>156</EndPage><MedlinePgn>137-156</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jare.2023.03.007</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2090-1232(23)00089-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Enterovirus A71 (EV-A71) is capable of causing hand, foot and mouth disease (HFMD), which may lead to neurological sequelae and even death. As EV-A71 is resistant to environmental changes and mutates easily, there is still a lack of effective treatments or globally available vaccines.</AbstractText><AbstractText Label="AIM OF REVIEW" NlmCategory="OBJECTIVE">For more than 50 years since the HFMD epidemic, related drug research has been conducted. Progress in this area can promote the further application of existing potential drugs and develop more efficient and safe antiviral drugs, and provide useful reference for protecting the younger generation and maintaining public health security.</AbstractText><AbstractText Label="KEY SCIENTIFIC CONCEPTS OF REVIEW" NlmCategory="UNASSIGNED">At present, researchers have identified hundreds of EV-A71 inhibitors based on screening repurposed drugs, targeted structural design, and rational modification of previously effective drugs as the main development strategies. This review systematically introduces the current potential drugs to inhibit EV-A71 infection, including viral inhibitors targeting key sites such as the viral capsid, RNA-dependent RNA polymerase (RdRp), 2C protein, internal ribosome entry site (IRES), 3C proteinase (3C<sup>pro</sup>), and 2A proteinase (2A<sup>pro</sup>), starting from each stage of the viral life cycle. Meanwhile, the progress of host-targeting antiviral drugs and their development are summarized in terms of regulating host immunity, inhibiting autophagy or apoptosis, and regulating the cellular redox environment. In addition, the current clinical methods for the prevention and treatment of HFMD are summarized and discussed with the aim of providing support and recommendations for the treatment of enterovirus infections including EV-A71.</AbstractText><CopyrightInformation>Copyright © 2024. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shuqi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pang</LastName><ForeName>Zehan</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Huahao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: fanhuahao@mail.buct.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Yigang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China; Beijing Advanced Innovation Center for Soft Matter Science and Engineering, Beijing University of Chemical Technology, Beijing, China. Electronic address: tongyigang@mail.buct.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Adv Res</MedlineTA><NlmUniqueID>101546952</NlmUniqueID><ISSNLinking>2090-1224</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076722" MajorTopicYN="N">Drug Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antivirals</Keyword><Keyword MajorTopicYN="N">Drug design and discovery</Keyword><Keyword MajorTopicYN="N">Drug therapy</Keyword><Keyword MajorTopicYN="N">Enterovirus A71</Keyword><Keyword MajorTopicYN="N">Hand, foot and mouth disease</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>31</Day><Hour>19</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37001813</ArticleId><ArticleId IdType="pmc">PMC10834817</ArticleId><ArticleId IdType="doi">10.1016/j.jare.2023.03.007</ArticleId><ArticleId IdType="pii">S2090-1232(23)00089-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schmidt N.J., Lennette E.H., Ho H.H. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129(3):304–309.</Citation><ArticleIdList><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen W.C., Chiu H.H., Chow K.C., Tsai C.H. MR imaging findings of enteroviral encephaloymelitis: an outbreak in Taiwan. AJNR Am J Neuroradiol. 1999;20(10):1889–1895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7657785</ArticleId><ArticleId IdType="pubmed">10588115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Lai J.K., Sam I.C., Chan Y.F. Recent developments in antiviral agents against enterovirus 71 infection. J Biomed Sci. 2014;21(1):14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3924904</ArticleId><ArticleId IdType="pubmed">24521134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M., Chen E.R., Hsu K.H., et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med. 1999;341(13):929–935.</Citation><ArticleIdList><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu F., Xu W., Xia J., et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370(9):818–828.</Citation><ArticleIdList><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiener T.K., Jia Q., Meng T., Chow V.T., Kwang J. A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved “knob” region of VP3 protein. PLoS Negl Trop Dis. 2014;8(5):e2895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4038473</ArticleId><ArticleId IdType="pubmed">24875055</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M., Yang X., Guan C., Wen T., Duan Y., Zhang W., et al. Andrographolide sulfonate reduces mortality in Enterovirus 71 infected mice by modulating immunity. Int Immunopharmacol. 2018;55:142–150.</Citation><ArticleIdList><ArticleId IdType="pubmed">29253820</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J., van Kuppeveld F. The life cycle of non-polio enteroviruses and how to target it. Nat Rev Microbiol. 2018;16(6):368–381.</Citation><ArticleIdList><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn P.C. Recent advances in the molecular epidemiology and control of human enterovirus 71 infection. Curr Opin Virol. 2012;2(2):199–205.</Citation><ArticleIdList><ArticleId IdType="pubmed">22482716</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A., Ekins S., Schmidtke M., Makarov V. Back to the future: advances in development of broad-spectrum capsid-binding inhibitors of enteroviruses. Eur J Med Chem. 2019;178:606–622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Dang M., Wang X., Wang Q., et al. Molecular mechanism of SCARB2-mediated attachment and uncoating of EV71. Protein Cell. 2014;5(9):692–703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4145081</ArticleId><ArticleId IdType="pubmed">24986489</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 antivirals: past, present, and future. Acta Pharm Sin B. 2022;12(4):1542–1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z.F., Gui J.J., Hua Q.H., Dong C.Z. Molecular epidemiology and evolution of human enterovirus 71 and hand, foot and mouth disease. Yi Chuan. 2015;37(5):426–435.</Citation><ArticleIdList><ArticleId IdType="pubmed">25998430</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu L., Qi M., Ma C., et al. Natural intertypic and intratypic recombinants of enterovirus 71 from mainland China during 2009–2018: a complete genome analysis. Virus Genes. 2021;57(2):172–180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7877514</ArticleId><ArticleId IdType="pubmed">33575934</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Yamashita Y., Li J., et al. Scavenger receptor B2 is a cellular receptor for enterovirus 71. Nat Med. 2009;15(7):798–801.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543282</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Shimojima M., Tano Y., Miyamura T., Wakita T., Shimizu H. Human P-selectin glycoprotein ligand-1 is a functional receptor for enterovirus 71. Nat Med. 2009;15(7):794–797.</Citation><ArticleIdList><ArticleId IdType="pubmed">19543284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang S.L., Chou Y.T., Wu C.N., Ho M.S. Annexin II binds to capsid protein VP1 of enterovirus 71 and enhances viral infectivity. J Virol. 2011;85(22):11809–11820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3209289</ArticleId><ArticleId IdType="pubmed">21900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Poh C.L., Sam I.C., Chan Y.F. Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor. J Virol. 2013;87(1):611–620.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536405</ArticleId><ArticleId IdType="pubmed">23097443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B., Chuang H., Yang K.D. Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J. 2009;6:141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2751754</ArticleId><ArticleId IdType="pubmed">19751532</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamayoshi S., Fujii K., Koike S. Receptors for enterovirus 71. Emerg Microbes Infect. 2014;3(7):e53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4126179</ArticleId><ArticleId IdType="pubmed">26038749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.W., Lin H.Y., Tsou Y.L., et al. Human SCARB2-mediated entry and endocytosis of EV71. PLoS One. 2012;7(1):e30507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3260287</ArticleId><ArticleId IdType="pubmed">22272359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussain K.M., Leong K.L., Ng M.M., Chu J.J. The essential role of clathrin-mediated endocytosis in the infectious entry of human enterovirus 71. J Biol Chem. 2011;286(1):309–321.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3012988</ArticleId><ArticleId IdType="pubmed">20956521</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi K., Koike S. Cellular receptors for enterovirus A71. J Biomed Sci. 2020;27(1):23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6954530</ArticleId><ArticleId IdType="pubmed">31924205</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T., Lewthwaite P., Perera D., Cardosa M.J., McMinn P., Ooi M.H. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis. 2010;10(11):778–790.</Citation><ArticleIdList><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L., Lu J., Kung H.F., He M.L. The virology and developments toward control of human enterovirus 71. Crit Rev Microbiol. 2011;37(4):313–327.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Hong W.J., Chu J.J. Inhibition of enterovirus VP4 myristoylation is a potential antiviral strategy for hand, foot and mouth disease. Antiviral Res. 2016;133:191–195.</Citation><ArticleIdList><ArticleId IdType="pubmed">27520386</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.Y., Li M.L., Shih S.R. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucleic Acids Res. 2009;37(1):47–59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615614</ArticleId><ArticleId IdType="pubmed">19010963</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Yang P., Wang N., et al. The binding of a monoclonal antibody to the apical region of SCARB2 blocks EV71 infection. Protein Cell. 2017;8(8):590–600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5546930</ArticleId><ArticleId IdType="pubmed">28447294</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu L, Xu K, Wang N, et al. Neutralization mechanisms of two highly potent antibodies against human enterovirus 71. mBio. 2018;9(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6030555</ArticleId><ArticleId IdType="pubmed">29970466</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chan Y.F., Sim K.M., Tan E.L., Poh C.L. Inhibition of enterovirus 71 (EV-71) infections by a novel antiviral peptide derived from EV-71 capsid protein VP1. PLoS One. 2012;7(5):e34589.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3341398</ArticleId><ArticleId IdType="pubmed">22563456</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Zhou H., Zhang X., et al. Acarbose, as a potential drug, effectively blocked the dynamic metastasis of EV71 from the intestine to the whole body. Infect Genet Evol. 2020;81</Citation><ArticleIdList><ArticleId IdType="pubmed">32004757</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X.X., Li C., Xiong S.D., Huang Z., Wang J.H., Wang H.B. Antibodies to P-selectin glycoprotein ligand-1 block dendritic cell-mediated enterovirus 71 transmission and prevent virus-induced cells death. Virulence. 2015;6(8):802–808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4826143</ArticleId><ArticleId IdType="pubmed">26399965</ArticleId></ArticleIdList></Reference><Reference><Citation>Earley D.F., Bailly B., Maggioni A., et al. Efficient blocking of enterovirus 71 infection by heparan sulfate analogues acting as decoy receptors. ACS Infect Dis. 2019;5(10):1708–1717.</Citation><ArticleIdList><ArticleId IdType="pubmed">31307190</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H.R., Poh C.L., Fecondo J., Grollo L. In vitro evaluation of the antiviral activity of heparan sulfate mimetic compounds against Enterovirus 71. Virus Res. 2012;169(1):22–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">22771616</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourianfar H.R., Palombo E., Grollo L. Global impact of heparin on gene expression profiles in neural cells infected by enterovirus 71. Intervirology. 2014;57(2):93–100.</Citation><ArticleIdList><ArticleId IdType="pubmed">24281657</ArticleId></ArticleIdList></Reference><Reference><Citation>Ku Z., Ye X., Shi J., Wang X., Liu Q., Huang Z. Single neutralizing monoclonal antibodies targeting the VP1 GH loop of enterovirus 71 inhibit both virus attachment and internalization during viral entry. J Virol. 2015;89(23):12084–12095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4645313</ArticleId><ArticleId IdType="pubmed">26401034</ArticleId></ArticleIdList></Reference><Reference><Citation>Su P.Y., Wang Y.F., Huang S.W., et al. Cell surface nucleolin facilitates enterovirus 71 binding and infection. J Virol. 2015;89(8):4527–4538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4442404</ArticleId><ArticleId IdType="pubmed">25673703</ArticleId></ArticleIdList></Reference><Reference><Citation>Plevka P., Perera R., Yap M.L., Cardosa J., Kuhn R.J., Rossmann M.G. Structure of human enterovirus 71 in complex with a capsid-binding inhibitor. Proc Natl Acad Sci U S A. 2013;110(14):5463–5467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3619292</ArticleId><ArticleId IdType="pubmed">23509286</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.L., Lin T.M., Wang S.Y., Wang J.R. The role of conserved arginine and proline residues in enterovirus VP1 protein. J Microbiol Immunol Infect. 2022;55(4):590–597.</Citation><ArticleIdList><ArticleId IdType="pubmed">35232679</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.L., Huang S.W., Shen C.Y., Cheng D., Wang J.R. Conserved residues adjacent to ß-barrel and loop intersection among enterovirus VP1 affect viral replication: potential target for anti-enteroviral development. Viruses. 2022;14(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877150</ArticleId><ArticleId IdType="pubmed">35215957</ArticleId></ArticleIdList></Reference><Reference><Citation>Reina J. Ballesteros F.[Pleconaril, a new aniviral drug with activity against picornavirus] Rev Esp Quimioter. 2000;13(3):257–262.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086273</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotbart H.A., Webster A.D. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. 2001;32(2):228–235.</Citation><ArticleIdList><ArticleId IdType="pubmed">11170912</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G., Zhou F., Gu B., et al. In vitro and in vivo evaluation of ribavirin and pleconaril antiviral activity against enterovirus 71 infection. Arch Virol. 2012;157(4):669–679.</Citation><ArticleIdList><ArticleId IdType="pubmed">22245989</ArticleId></ArticleIdList></Reference><Reference><Citation>Smee D.F., Evans W.J., Nicolaou K.C., Tarbet E.B., Day C.W. Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds. Antiviral Res. 2016;131:61–65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5100981</ArticleId><ArticleId IdType="pubmed">27063860</ArticleId></ArticleIdList></Reference><Reference><Citation>Shia K.S., Li W.T., Chang C.M., et al. Design, synthesis, and structure-activity relationship of pyridyl imidazolidinones: a novel class of potent and selective human enterovirus 71 inhibitors. J Med Chem. 2002;45(8):1644–1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">11931618</ArticleId></ArticleIdList></Reference><Reference><Citation>Chern J.H., Lee C.C., Chang C.S., et al. Synthesis and antienteroviral activity of a series of novel, oxime ether-containing pyridyl imidazolidinones. Bioorg Med Chem Lett. 2004;14(20):5051–5056.</Citation><ArticleIdList><ArticleId IdType="pubmed">15380197</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C., Liu S.C., Huang P.N., Chang H.Y., Chern J.H., Shih S.R. Antiviral activity of pyridyl imidazolidinones against enterovirus 71 variants. J Biomed Sci. 2008;15(3):291–300.</Citation><ArticleIdList><ArticleId IdType="pubmed">18196474</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C.S., Lin Y.T., Shih S.R., et al. Design, synthesis, and antipicornavirus activity of 1-[5-(4-arylphenoxy)alkyl]-3-pyridin-4-ylimidazolidin-2-one derivatives. J Med Chem. 2005;48(10):3522–3535.</Citation><ArticleIdList><ArticleId IdType="pubmed">15887961</ArticleId></ArticleIdList></Reference><Reference><Citation>De Colibus L., Wang X., Spyrou J., et al. More-powerful virus inhibitors from structure-based analysis of HEV71 capsid-binding molecules. Nat Struct Mol Biol. 2014;21(3):282–288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4530014</ArticleId><ArticleId IdType="pubmed">24509833</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H.Q., Wang Y., Mao Y.H., et al. The inactivation of the non-enveloped enterovirus 71 (EV71) by a novel disinfectant gel formulation for topical use. Drug Dev Ind Pharm. 2019;45(3):506–513.</Citation><ArticleIdList><ArticleId IdType="pubmed">30574810</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih S.R., Tsai M.C., Tseng S.N., et al. Mutation in enterovirus 71 capsid protein VP1 confers resistance to the inhibitory effects of pyridyl imidazolidinone. Antimicrob Agents Chemother. 2004;48(9):3523–3529.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC514779</ArticleId><ArticleId IdType="pubmed">15328120</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang M., Wang Y., He W., Sun Y., Guo Y., Zhong W., et al. Design, synthesis, and evaluation of novel enterovirus 71 inhibitors as therapeutic drug leads for the treatment of human hand, foot, and mouth disease. J Med Chem. 2020;63(3):1233–1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">31939669</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Li Y., Fan S., Cao R., Li X., He X., et al. Discovery and optimization of quinoline analogues as novel potent antivirals against enterovirus D68. J Med Chem. 2022;65(21):14792–14808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9661475</ArticleId><ArticleId IdType="pubmed">36254462</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Gualda B., Sun L., Martí-Marí O., et al. Scaffold simplification strategy leads to a novel generation of dual human immunodeficiency virus and enterovirus-A71 entry inhibitors. J Med Chem. 2020;63(1):349–368.</Citation><ArticleIdList><ArticleId IdType="pubmed">31809045</ArticleId></ArticleIdList></Reference><Reference><Citation>Martí-Marí O., Martínez-Gualda B., de la Puente-Secades S., et al. Double arylation of the indole side chain of tri- and tetrapodal tryptophan derivatives renders highly potent HIV-1 and EV-A71 entry inhibitors†. J Med Chem. 2021;64(14):10027–10046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389807</ArticleId><ArticleId IdType="pubmed">34229438</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez-Gualda B., Sun L., Martí-Marí O., et al. Modifications in the branched arms of a class of dual inhibitors of HIV and EV71 replication expand their antiviral spectrum. Antiviral Res. 2019;168:210–214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114229</ArticleId><ArticleId IdType="pubmed">31228490</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruiz-Santaquiteria M., Illescas B.M., Abdelnabi R., et al. Multivalent tryptophan- and tyrosine-containing[60]fullerene hexa-adducts as dual HIV and enterovirus A71 entry inhibitors. Chemistry. 2021;27(41):10700–10710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8361981</ArticleId><ArticleId IdType="pubmed">33851758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Qing J., Sun Y., Rao Z. Suramin inhibits EV71 infection. Antiviral Res. 2014;103:1–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24374150</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol. 2008;89(Pt 10):2518–2530.</Citation><ArticleIdList><ArticleId IdType="pubmed">18796721</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan S., Li G., Wang Y., et al. Identification of positively charged residues in enterovirus 71 capsid protein VP1 essential for production of infectious particles. J Virol. 2016;90(2):741–752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4702679</ArticleId><ArticleId IdType="pubmed">26512078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P., Zou G., Bailly B., et al. The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo. Emerg Microbes Infect. 2014;3(9):e62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4185360</ArticleId><ArticleId IdType="pubmed">26038755</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P., Zheng Y., Wang W., Hong L., Delpeyroux F., Arenzana-Seisdedos F., et al. Suramin interacts with the positively charged region surrounding the 5-fold axis of the EV-A71 capsid and inhibits multiple enterovirus A. Sci Rep. 2017;7:42902.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5317167</ArticleId><ArticleId IdType="pubmed">28218309</ArticleId></ArticleIdList></Reference><Reference><Citation>Kell D.B., Heyden E.L., Pretorius E. The biology of lactoferrin, an iron-binding protein that can help defend against viruses and bacteria. Front Immunol. 2020;11:1221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271924</ArticleId><ArticleId IdType="pubmed">32574271</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng T.Y., Chen L.C., Shyu H.W., et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells. Antiviral Res. 2005;67(1):31–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15916817</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.Y., Chu C., Chiu C.H. Lactoferrin inhibits enterovirus 71 infection of human embryonal rhabdomyosarcoma cells in vitro. J Infect Dis. 2002;186(8):1161–1164.</Citation><ArticleIdList><ArticleId IdType="pubmed">12355368</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen M.H., Chiu C.H., Huang Y.C., Lin T.Y. Effects of lactoferrin-containing formula in the prevention of enterovirus and rotavirus infection and impact on serum cytokine levels: a randomized trial. Chang Gung Med J. 2011;34(4):395–402.</Citation><ArticleIdList><ArticleId IdType="pubmed">21880194</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen H.L., Wang L.C., Chang C.H., et al. Recombinant porcine lactoferrin expressed in the milk of transgenic mice protects neonatal mice from a lethal challenge with enterovirus type 71. Vaccine. 2008;26(7):891–898.</Citation><ArticleIdList><ArticleId IdType="pubmed">18207613</ArticleId></ArticleIdList></Reference><Reference><Citation>McCann K.B., Lee A., Wan J., Roginski H., Coventry M.J. The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J Appl Microbiol. 2003;95(5):1026–1033.</Citation><ArticleIdList><ArticleId IdType="pubmed">14633031</ArticleId></ArticleIdList></Reference><Reference><Citation>Pietrantoni A., Ammendolia M.G., Tinari A., Siciliano R., Valenti P., Superti F. Bovine lactoferrin peptidic fragments involved in inhibition of Echovirus 6 in vitro infection. Antiviral Res. 2006;69(2):98–106.</Citation><ArticleIdList><ArticleId IdType="pubmed">16386316</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.C., Chang C.H. In vitro inhibition of enterovirus 71 infection with a nickel ion/chitosan microcomposite. Virus Res. 2014;190:17–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">24998885</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T., Jia Q., Wong S.M., Chua K.B. In vitro and in vivo inhibition of the infectivity of human enterovirus 71 by a sulfonated food azo dye, brilliant black BN. J Virol. 2019;93(17)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6694806</ArticleId><ArticleId IdType="pubmed">31167919</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L., Wang M., Chen Y., Hu T., Yang Y., Zhang Y., et al. Structure of the enterovirus D68 RNA-dependent RNA polymerase in complex with NADPH implicates an inhibitor binding site in the RNA template tunnel. J Struct Biol. 2020;211(1)</Citation><ArticleIdList><ArticleId IdType="pubmed">32353513</ArticleId></ArticleIdList></Reference><Reference><Citation>Glab-Ampai K., Kaewchim K., Thavorasak T., Saenlom T., Thepsawat W., Mahasongkram K., et al. Targeting emerging RNA viruses by engineered human superantibody to hepatitis C virus RNA-dependent RNA polymerase. Front Microbiol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9355540</ArticleId><ArticleId IdType="pubmed">35935185</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Yu J., Qi X., Yan H. Monoclonal antibody against EV71 3D(pol) inhibits the polymerase activity of RdRp and virus replication. BMC Immunol. 2019;20(1):6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343263</ArticleId><ArticleId IdType="pubmed">30669993</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z.H., Li C.M., Ling P., et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197(6):854–857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109938</ArticleId><ArticleId IdType="pubmed">18279075</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng T., Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol. 2014;88(10):5803–5815.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4019108</ArticleId><ArticleId IdType="pubmed">24623423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H., Kim C., Kim D.E., et al. Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. Antiviral Res. 2015;124:1–10.</Citation><ArticleIdList><ArticleId IdType="pubmed">26526589</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu N., Yang J., Zheng B., et al. The pyrimidine analog FNC potently inhibits the replication of multiple enteroviruses. J Virol. 2020;94(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7163137</ArticleId><ArticleId IdType="pubmed">32075935</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Wang Y., Qing J., et al. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral Res. 2014;112:47–58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25446894</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T.C., Chang H.Y., Lin P.F., et al. Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71. Antimicrob Agents Chemother. 2009;53(7):2740–2747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2704669</ArticleId><ArticleId IdType="pubmed">19414569</ArticleId></ArticleIdList></Reference><Reference><Citation>Velu A.B., Chen G.W., Hsieh P.T., et al. BPR-3P0128 inhibits RNA-dependent RNA polymerase elongation and VPg uridylylation activities of Enterovirus 71. Antiviral Res. 2014;112:18–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25448086</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Z., Li H., Zhang Z., Meng J., Mao D., Bai B., et al. Enterovirus 71 2C protein inhibits TNF-α-mediated activation of NF-κB by suppressing IκB kinase β phosphorylation. J Immunol. 2011;187(5):2202–2212.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810613</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y., Zhang R., Wu W., Duan G. Innate immunity evasion by enteroviruses linked to epidemic hand-foot-mouth disease. Front Microbiol. 2018;9:2422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6186807</ArticleId><ArticleId IdType="pubmed">30349526</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q., Zheng Z., Liu Y., Zhang Z., Liu Q., Meng J., et al. 2C proteins of enteroviruses suppress IKKβ phosphorylation by recruiting protein phosphatase 1. J Virol. 2016;90(10):5141–5151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4859720</ArticleId><ArticleId IdType="pubmed">26962213</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji L., Yang E., He S., Jin Y., Chen D. Enterovirus 2C protein suppresses IKKα phosphorylation by recruiting IKKβ and IKKα into viral inclusion bodies. Viral Immunol. 2021;34(4):218–226.</Citation><ArticleIdList><ArticleId IdType="pubmed">33226912</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan H., Tian J., Qin B., Wojdyla J.A., Wang B., Zhao Z., et al. Crystal structure of 2C helicase from enterovirus 71. Sci Adv. 2017;3(4):e1602573.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5409451</ArticleId><ArticleId IdType="pubmed">28508043</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y., Wang C., Wang C., Yang R., Bai P., Zhang X.Y., et al. Antiviral peptides targeting the helicase activity of enterovirus nonstructural protein 2C. J Virol. 2021;95(12)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8315976</ArticleId><ArticleId IdType="pubmed">33789997</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Musharrafieh R., Zheng M., Wang J. Enterovirus D68 antivirals: past, present, and future. ACS Infect Dis. 2020;6(7):1572–1586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055446</ArticleId><ArticleId IdType="pubmed">32352280</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Manganaro R., Zonsics B., Hurdiss D.L., Zwaagstra M., Donselaar T., et al. Rational design of highly potent broad-spectrum enterovirus inhibitors targeting the nonstructural protein 2C. PLoS Biol. 2020;18(11):e3000904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7673538</ArticleId><ArticleId IdType="pubmed">33156822</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R., Zhang J., Tuohy P., Kitamura N., Bellampalli S.S., Hu Y., et al. Discovery of quinoline analogues as potent antivirals against enterovirus D68 (EV-D68) J Med Chem. 2019;62(8):4074–4090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8055447</ArticleId><ArticleId IdType="pubmed">30912944</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R., Kitamura N., Hu Y., Wang J. Development of broad-spectrum enterovirus antivirals based on quinoline scaffold. Bioorg Chem. 2020;101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390679</ArticleId><ArticleId IdType="pubmed">32559580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Q., Xu Z., Jin M., Shu T., Chen Y., Feng L., et al. Identification of dibucaine derivatives as novel potent enterovirus 2C helicase inhibitors: in vitro, in vivo, and combination therapy study. Eur J Med Chem. 2020;202</Citation><ArticleIdList><ArticleId IdType="pubmed">32619885</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y., Zuo J., Krogstad P., Jung M.E. Synthesis and structure-activity relationship (SAR) studies of novel pyrazolopyridine derivatives as inhibitors of enterovirus replication. J Med Chem. 2018;61(4):1688–1703.</Citation><ArticleIdList><ArticleId IdType="pubmed">29346733</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Kitamura N., Musharrafieh R., Wang J. Discovery of potent and broad-spectrum pyrazolopyridine-containing antivirals against enteroviruses D68, A71, and coxsackievirus B3 by targeting the viral 2C protein. J Med Chem. 2021;64(12):8755–8774.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9179928</ArticleId><ArticleId IdType="pubmed">34085827</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Jian X., Yin P., Zhu G., Zhang L. Elucidating the host interactome of EV-A71 2C reveals viral dependency factors. Front Microbiol. 2019;10:636.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454016</ArticleId><ArticleId IdType="pubmed">31001221</ArticleId></ArticleIdList></Reference><Reference><Citation>Horova V., Lyoo H., Różycki B., Chalupska D., Smola M., Humpolickova J., et al. Convergent evolution in the mechanisms of ACBD3 recruitment to picornavirus replication sites. PLoS Pathog. 2019;15(8):e1007962.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6695192</ArticleId><ArticleId IdType="pubmed">31381608</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Yuan S., Zhang C., et al. Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A. Antimicrob Agents Chemother. 2015;59(5):2654–2665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.X., Chu J.J. Antiviral screen identifies EV71 inhibitors and reveals camptothecin-target, DNA topoisomerase 1 as a novel EV71 host factor. Antiviral Res. 2017;143:122–133.</Citation><ArticleIdList><ArticleId IdType="pubmed">28427827</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang P.N., Lin J.Y., Locker N., et al. Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res. 2011;39(22):9633–9648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3239202</ArticleId><ArticleId IdType="pubmed">21880596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin J.Y., Shih S.R., Pan M., et al. hnRNP A1 interacts with the 5' untranslated regions of enterovirus 71 and Sindbis virus RNA and is required for viral replication. J Virol. 2009;83(12):6106–6114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2687368</ArticleId><ArticleId IdType="pubmed">19339352</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolbert M., Morgan C.E., Pollum M., et al. HnRNP A1 alters the structure of a conserved enterovirus IRES domain to stimulate viral translation. J Mol Biol. 2017;429(19):2841–2858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610934</ArticleId><ArticleId IdType="pubmed">28625847</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou H.Y., Lu W.W., Wu K.Y., Lin C.W., Kung S.H. Idarubicin is a broad-spectrum enterovirus replication inhibitor that selectively targets the virus internal ribosomal entry site. J Gen Virol. 2016;97(5):1122–1133.</Citation><ArticleIdList><ArticleId IdType="pubmed">26879094</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Qiao H., Lv Y., et al. Apigenin inhibits enterovirus-71 infection by disrupting viral RNA association with trans-acting factors. PLoS One. 2014;9(10):e110429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4199717</ArticleId><ArticleId IdType="pubmed">25330384</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji P., Chen C., Hu Y., et al. Antiviral activity of Paulownia tomentosa against enterovirus 71 of hand, foot, and mouth disease. Biol Pharm Bull. 2015;38(1):1–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25744451</ArticleId></ArticleIdList></Reference><Reference><Citation>Davila-Calderon J., Patwardhan N.N., Chiu L.Y., et al. IRES-targeting small molecule inhibits enterovirus 71 replication via allosteric stabilization of a ternary complex. Nat Commun. 2020;11(1):4775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7508794</ArticleId><ArticleId IdType="pubmed">32963221</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai F.J., Lin C.W., Lai C.C., et al. Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins. Food Chem. 2011;128(2):312–322.</Citation><ArticleIdList><ArticleId IdType="pubmed">25212137</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Du J., Wu Z., Jin Q. Quinacrine impairs enterovirus 71 RNA replication by preventing binding of polypyrimidine-tract binding protein with internal ribosome entry sites. PLoS One. 2013;8(1):e52954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3536785</ArticleId><ArticleId IdType="pubmed">23301007</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y.J., Zeng S.J., Hsu J.T., et al. Amantadine as a regulator of internal ribosome entry site. Acta Pharmacol Sin. 2008;29(11):1327–1333.</Citation><ArticleIdList><ArticleId IdType="pubmed">18954527</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan C.W., Chan Y.F., Quah Y.W., Poh C.L. Inhibition of enterovirus 71 infection by antisense octaguanidinium dendrimer-conjugated morpholino oligomers. Antiviral Res. 2014;107:35–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118997</ArticleId><ArticleId IdType="pubmed">24769243</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H.I., Chio C.C., Lin J.Y. Inhibition of EV71 by curcumin in intestinal epithelial cells. PLoS One. 2018;13(1):e0191617.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5784943</ArticleId><ArticleId IdType="pubmed">29370243</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Huang Y., Sun M., et al. Honeysuckle-encoded microRNA2911 inhibits enterovirus 71 replication via targeting VP1 gene. Antiviral Res. 2018;152:117–123.</Citation><ArticleIdList><ArticleId IdType="pubmed">29458129</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Z., Li Y., Xu T., et al. Inhibition of enterovirus 71 by selenium nanoparticles loaded with siRNA through bax signaling pathways. ACS Omega. 2020;5(21):12495–12500.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271353</ArticleId><ArticleId IdType="pubmed">32548434</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W., Qi Z., Wang J. The function and mechanism of enterovirus 71 (EV71) 3C protease. Curr Microbiol. 2020;77(9):1968–1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">32556480</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Yue Y., Zhang Y., Yuan Z., Li P., Song N., et al. A novel enterovirus 71 (EV71) virulence determinant: the 69th residue of 3C protease modulates pathogenicity. Front Cell Infect Microbiol. 2017;7:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5290453</ArticleId><ArticleId IdType="pubmed">28217559</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.N., Song Z.G., Jiang T., Shi B.S., Hu Y.W., Yuan Z.H. Rupintrivir is a promising candidate for treating severe cases of Enterovirus-71 infection. World J Gastroenterol. 2010;16(2):201–209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806558</ArticleId><ArticleId IdType="pubmed">20066739</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Song Z., Qin B., et al. Rupintrivir is a promising candidate for treating severe cases of enterovirus-71 infection: evaluation of antiviral efficacy in a murine infection model. Antiviral Res. 2013;97(3):264–269.</Citation><ArticleIdList><ArticleId IdType="pubmed">23295352</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H.Y., Lu C.Y., Tsao K.C., et al. Association of EV71 3C polymorphisms with clinical severity. J Microbiol Immunol Infect. 2018;51(5):608–613.</Citation><ArticleIdList><ArticleId IdType="pubmed">28711442</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu G., Qi J., Chen Z., et al. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J Virol. 2011;85(19):10319–10331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196414</ArticleId><ArticleId IdType="pubmed">21795339</ArticleId></ArticleIdList></Reference><Reference><Citation>Hung H.C., Wang H.C., Shih S.R., Teng I.F., Tseng C.P., Hsu J.T. Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir. J Infect Dis. 2011;203(12):1784–1790.</Citation><ArticleIdList><ArticleId IdType="pubmed">21536800</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Jochmans D., Xie H., et al. Design, synthesis, and biological evaluation of peptidomimetic aldehydes as broad-spectrum inhibitors against enterovirus and SARS-CoV-2. J Med Chem. 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">33872498</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan J., George S., Kusov Y., et al. 3C protease of enterovirus 68: structure-based design of Michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses. J Virol. 2013;87(8):4339–4351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3624371</ArticleId><ArticleId IdType="pubmed">23388726</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix C., George S., Leyssen P., Hilgenfeld R., Neyts J. The enterovirus 3C protease inhibitor SG85 efficiently blocks rhinovirus replication and is not cross-resistant with rupintrivir. Antimicrob Agents Chemother. 2015;59(9):5814–5818.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4538484</ArticleId><ArticleId IdType="pubmed">26055377</ArticleId></ArticleIdList></Reference><Reference><Citation>Jetsadawisut W., Nutho B., Meeprasert A., Rungrotmongkol T., Kungwan N., Wolschann P., et al. Susceptibility of inhibitors against 3C protease of coxsackievirus A16 and enterovirus A71 causing hand, foot and mouth disease: a molecular dynamics study. Biophys Chem. 2016;219:9–16.</Citation><ArticleIdList><ArticleId IdType="pubmed">27668727</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Yang B., Hao F., et al. Design, synthesis, and biological evaluation of anti-EV71 agents. Bioorg Med Chem Lett. 2016;26(14):3346–3350.</Citation><ArticleIdList><ArticleId IdType="pubmed">27234148</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M., Xu B., Ma Y., Shang L., Ye S., Wang Y. Reversible covalent inhibitors suppress enterovirus 71 infection by targeting the 3C protease. Antiviral Res. 2021;192</Citation><ArticleIdList><ArticleId IdType="pubmed">34082057</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Cao L., Zhai Y., Yin Z., Sun Y., Shang L. Structure of the enterovirus 71 3C protease in complex with NK-1.8k and indications for the development of antienterovirus protease inhibitor. Antimicrob Agents Chemother. 2017;61(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5487676</ArticleId><ArticleId IdType="pubmed">28461310</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Yang B., Zhai Y., Yin Z., Sun Y., Rao Z. Peptidyl aldehyde NK-1.8k suppresses enterovirus 71 and enterovirus 68 infection by targeting protease 3C. Antimicrob Agents Chemother. 2015;59(5):2636–2646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394787</ArticleId><ArticleId IdType="pubmed">25691647</ArticleId></ArticleIdList></Reference><Reference><Citation>Ang M.J., Lau Q.Y., Ng F.M., et al. Peptidomimetic ethyl propenoate covalent inhibitors of the enterovirus 71 3C protease: a P2–P4 study. J Enzyme Inhib Med Chem. 2016;31(2):332–339.</Citation><ArticleIdList><ArticleId IdType="pubmed">25792507</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y., Ma Y., Ma F., et al. Structure-activity relationship study of peptidomimetic aldehydes as enterovirus 71 3C protease inhibitors. Eur J Med Chem. 2016;124:559–573.</Citation><ArticleIdList><ArticleId IdType="pubmed">27614190</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Ang M.J., Lau Q.Y., et al. Antiviral activities of peptide-based covalent inhibitors of the Enterovirus 71 3C protease. Sci Rep. 2016;6:33663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5028882</ArticleId><ArticleId IdType="pubmed">27645381</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai Y., Zhao X., Cui Z., et al. Cyanohydrin as an anchoring group for potent and selective inhibitors of enterovirus 71 3C protease. J Med Chem. 2015;58(23):9414–9420.</Citation><ArticleIdList><ArticleId IdType="pubmed">26571192</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Shang C., Yang P., et al. 4-Iminooxazolidin-2-one as a bioisostere of the cyanohydrin moiety: inhibitors of enterovirus 71 3C protease. J Med Chem. 2018;61(22):10333–10339.</Citation><ArticleIdList><ArticleId IdType="pubmed">30365311</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu B., Liu M., Ma S., et al. 4-Iminooxazolidin-2-one as a bioisostere of cyanohydrin suppresses EV71 proliferation by targeting 3C(pro) Microbiol Spectr. 2021;9(3):e0102521.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8597634</ArticleId><ArticleId IdType="pubmed">34787443</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma G.H., Ye Y., Zhang D., et al. Identification and biochemical characterization of DC07090 as a novel potent small molecule inhibitor against human enterovirus 71 3C protease by structure-based virtual screening. Eur J Med Chem. 2016;124:981–991.</Citation><ArticleIdList><ArticleId IdType="pubmed">27776325</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z., Ding Y., Ke Z., et al. Luteoloside acts as 3C protease inhibitor of enterovirus 71 in vitro. PLoS One. 2016;11(2):e0148693.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4752227</ArticleId><ArticleId IdType="pubmed">26870944</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang L., Xu M., Yin Z. Antiviral drug discovery for the treatment of enterovirus 71 infections. Antiviral Res. 2013;97(2):183–194.</Citation><ArticleIdList><ArticleId IdType="pubmed">23261847</ArticleId></ArticleIdList></Reference><Reference><Citation>Norder H., De Palma A.M., Selisko B., et al. Picornavirus non-structural proteins as targets for new anti-virals with broad activity. Antiviral Res. 2011;89(3):204–218.</Citation><ArticleIdList><ArticleId IdType="pubmed">21236302</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zou W., Niu Y., Wang S., Chen B., Xiong R., et al. Phosphorylation of enteroviral 2A(pro) at Ser/Thr125 benefits its proteolytic activity and viral pathogenesis. J Med Virol. 2023;95(1):e28400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10107306</ArticleId><ArticleId IdType="pubmed">36511115</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Lei X., Xiao X., et al. Reciprocal regulation between enterovirus 71 and the NLRP3 inflammasome. Cell Rep. 2015;12(1):42–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">26119741</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Xi X., Lei X., et al. Enterovirus 71 protease 2Apro targets MAVS to inhibit anti-viral type I interferon responses. PLoS Pathog. 2013;9(3):e1003231.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605153</ArticleId><ArticleId IdType="pubmed">23555247</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q., Yameen M., Liu W., Gao Z., Li Y., Peng X., et al. Conformational plasticity of the 2A proteinase from enterovirus 71. J Virol. 2013;87(13):7348–7356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3700279</ArticleId><ArticleId IdType="pubmed">23616646</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Liu Y., Hou X., et al. Chlorogenic acid inhibits the replication and viability of enterovirus 71 in vitro. PLoS One. 2013;8(9):e76007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3786884</ArticleId><ArticleId IdType="pubmed">24098754</ArticleId></ArticleIdList></Reference><Reference><Citation>Falah N., Montserret R., Lelogeais V., et al. Blocking human enterovirus 71 replication by targeting viral 2A protease. J Antimicrob Chemother. 2012;67(12):2865–2869.</Citation><ArticleIdList><ArticleId IdType="pubmed">22865380</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.G., Cheng M.L., Chen K.H., et al. Antiviral activities of Schizonepeta tenuifolia Briq. against enterovirus 71 in vitro and in vivo. Sci Rep. 2017;7(1):935.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430552</ArticleId><ArticleId IdType="pubmed">28428548</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S.G., Leu Y.L., Cheng M.L., et al. Anti-enterovirus 71 activities of Melissa officinalis extract and its biologically active constituent rosmarinic acid. Sci Rep. 2017;7(1):12264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5613005</ArticleId><ArticleId IdType="pubmed">28947773</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Wang X., Wang Y., Pei X., Wang C., Niu Y., et al. Substituted 3-benzylcoumarins 13 and 14 suppress enterovirus A71 replication by impairing viral 2A(pro) dependent IRES-driven translation. Antiviral Res. 2018;160:10–16.</Citation><ArticleIdList><ArticleId IdType="pubmed">30315876</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R., Ma C., Zhang J., Hu Y., Diesing J.M., Marty M.T., et al. Validating enterovirus D68–2A(pro) as an antiviral drug target and the discovery of telaprevir as a potent D68–2A(pro) inhibitor. J Virol. 2019;93(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6430540</ArticleId><ArticleId IdType="pubmed">30674624</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Yao Y., Chen Y., et al. Enterovirus 71 3C promotes apoptosis through cleavage of PinX1, a telomere binding protein. J Virol. 2017;91(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5215332</ArticleId><ArticleId IdType="pubmed">27847364</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Wu Y., Bi J., et al. Antiviral effects of Retro-2(cycl) and Retro-2.1 against Enterovirus 71 in vitro and in vivo. Antiviral Res. 2017;144:311–321.</Citation><ArticleIdList><ArticleId IdType="pubmed">28688753</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.Y., Xi X.Y., Zhao Z.D. [Autophagy inhibitor 3-MA decreases the production and release of infectious enterovirus 71 particles] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2011;25(3):176–178.</Citation><ArticleIdList><ArticleId IdType="pubmed">21977584</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox J.A., Hiscox J.A., Solomon T., Ooi M.H., Ng L. Immunopathogenesis and virus-host interactions of enterovirus 71 in patients with hand. Foot Mouth Disease Front Microbiol. 2017;8:2249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5713468</ArticleId><ArticleId IdType="pubmed">29238324</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasti M., Khanbabaei H., Teimoori A. An update on enterovirus 71 infection and interferon type I response. Rev Med Virol. 2019;29(1):e2016.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169063</ArticleId><ArticleId IdType="pubmed">30378208</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B., Zheng J. MicroR-9-5p suppresses EV71 replication through targeting NFκB of the RIG-I-mediated innate immune response. FEBS Open Bio. 2018;8(9):1457–1470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6120239</ArticleId><ArticleId IdType="pubmed">30186747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Zhao B., Chen X., et al. GS-9620 inhibits enterovirus 71 replication mainly through the NF-κB and PI3K-AKT signaling pathways. Antiviral Res. 2018;153:39–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">29425831</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Li Y., Gu Z., et al. Resveratrol inhibits enterovirus 71 replication and pro-inflammatory cytokine secretion in rhabdosarcoma cells through blocking IKKs/NF-κB signaling pathway. PLoS One. 2015;10(2):e0116879.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333343</ArticleId><ArticleId IdType="pubmed">25692777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Han H., Sun L., et al. Antiviral activity of shikonin ester derivative PMM-034 against enterovirus 71 in vitro. Braz J Med Biol Res. 2017;50(10):e6586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5561812</ArticleId><ArticleId IdType="pubmed">28832767</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Wang P., Chen X., Wang W., Jin Y. Saururus chinensis (Lour.) Baill blocks enterovirus 71 infection by hijacking MEK1-ERK signaling pathway. Antiviral Res. 2015;119:47–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">25912818</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Dai Y., Fu Y., et al. Cathelicidin antimicrobial peptides suppress EV71 infection via regulating antiviral response and inhibiting viral binding. Antiviral Res. 2021;187</Citation><ArticleIdList><ArticleId IdType="pubmed">33508330</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Niu Y., Wang C., et al. Discovery of 3-benzyl-1,3-benzoxazine-2,4-dione analogues as allosteric mitogen-activated kinase kinase (MEK) inhibitors and anti-enterovirus 71 (EV71) agents. Bioorg Med Chem. 2016;24(16):3472–3482.</Citation><ArticleIdList><ArticleId IdType="pubmed">27288186</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.L., Lee Y.P., Wang Y.F., et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol. 2005;86(Pt 12):3263–3269.</Citation><ArticleIdList><ArticleId IdType="pubmed">16298971</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Zhang X., Wang F., et al. Clinical efficacy of therapy with recombinant human interferon α1b in hand, foot, and mouth disease with enterovirus 71 infection. PLoS One. 2016;11(2):e0148907.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4755579</ArticleId><ArticleId IdType="pubmed">26882102</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin C.W., Wu C.F., Hsiao N.W., et al. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents. 2008;32(4):355–359.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126984</ArticleId><ArticleId IdType="pubmed">18701259</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S., Yang Y., Xu J., Su L., Wang W. Effect of all-trans-retinoic acid on enterovirus 71 infection in vitro. Br J Nutr. 2014;111(9):1586–1593.</Citation><ArticleIdList><ArticleId IdType="pubmed">24495389</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang N.X., Zou Y., Liang Q.H., et al. Anemoside B4 inhibits enterovirus 71 propagation in mice through upregulating 14-3-3 expression and type I interferon responses. Acta Pharmacol Sin. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976028</ArticleId><ArticleId IdType="pubmed">34321612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang N., Gao H., He L., et al. Ginsenoside Rb1 is an immune-stimulatory agent with antiviral activity against enterovirus 71. J Ethnopharmacol. 2021;266</Citation><ArticleIdList><ArticleId IdType="pubmed">32980486</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao W.W., Kuo Y.H., Lin B.F. Isolation and identification of andrographis paniculata (Chuanxinlian) and its biologically active constituents inhibited enterovirus 71-induced cell apoptosis. Front Pharmacol. 2021;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8692857</ArticleId><ArticleId IdType="pubmed">34955832</ArticleId></ArticleIdList></Reference><Reference><Citation>Liou A.T., Liao C.C., Chou S.F., Chang Y.S., Chang C.S., Shih C. Hypoxia and therapeutic treatment of EV-A71 with an immune modulator TLR7 agonist in a new immunocompetent mouse model. J Biomed Sci. 2019;26(1):93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6849267</ArticleId><ArticleId IdType="pubmed">31711481</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Xie J., Xu X., et al. MicroRNA-548 down-regulates host antiviral response via direct targeting of IFN-λ1. Protein Cell. 2013;4(2):130–141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4875363</ArticleId><ArticleId IdType="pubmed">23150165</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho B.C., Yu I.S., Lu L.F., et al. Inhibition of miR-146a prevents enterovirus-induced death by restoring the production of type I interferon. Nat Commun. 2014;5:3344.</Citation><ArticleIdList><ArticleId IdType="pubmed">24561744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M., Liu C.C. Enterovirus 71: epidemiology, pathogenesis and management. Expert Rev Anti Infect Ther. 2009;7(6):735–742.</Citation><ArticleIdList><ArticleId IdType="pubmed">19681701</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.M., Lei H.Y., Huang M.C., et al. Modulation of cytokine production by intravenous immunoglobulin in patients with enterovirus 71-associated brainstem encephalitis. J Clin Virol. 2006;37(1):47–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">16861032</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sanden S.M., Koen G., van Eijk H., Koekkoek S.M., de Jong M.D., Wolthers K.C. Prediction of protection against asian enterovirus 71 outbreak strains by cross-neutralizing capacity of serum from dutch donors. Netherlands Emerg Infect Dis. 2016;22(9):1562–1569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4994357</ArticleId><ArticleId IdType="pubmed">27533024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.Y., Wang H.C., Wang K.T., et al. Neutralization of five subgenotypes of Enterovirus 71 by Taiwanese human plasma and Taiwanese plasma derived intravenous immunoglobulin. Biologicals. 2013;41(3):154–157.</Citation><ArticleIdList><ArticleId IdType="pubmed">23515089</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnard D.L. Current status of anti-picornavirus therapies. Curr Pharm Des. 2006;12(11):1379–1390.</Citation><ArticleIdList><ArticleId IdType="pubmed">16611122</ArticleId></ArticleIdList></Reference><Reference><Citation>Techasaensiri C., Wongsa A., Puthanakit T., et al. Response of severe EV71-infected patients to hyperimmune plasma treatment: a pilot study. Pathogens. 2021;10(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8161181</ArticleId><ArticleId IdType="pubmed">34069574</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg-Lerner A., Bialik S., Simon H.U., Kimchi A. Life and death partners: apoptosis, autophagy and the cross-talk between them. Cell Death Differ. 2009;16(7):966–975.</Citation><ArticleIdList><ArticleId IdType="pubmed">19325568</ArticleId></ArticleIdList></Reference><Reference><Citation>Xi X., Zhang X., Wang B., et al. The interplays between autophagy and apoptosis induced by enterovirus 71. PLoS One. 2013;8(2):e56966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3577684</ArticleId><ArticleId IdType="pubmed">23437282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.R., Wang P.S., Wang J.R., Liu H.S. Enterovirus 71-induced autophagy increases viral replication and pathogenesis in a suckling mouse model. J Biomed Sci. 2014;21(1):80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4237791</ArticleId><ArticleId IdType="pubmed">25139436</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang B., Zhu Y., Liu L., et al. Enterovirus 71 induces autophagy in mice via mTOR inhibition and ERK pathway activation. Life Sci. 2021;271</Citation><ArticleIdList><ArticleId IdType="pubmed">33581126</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang S.C., Chang C.L., Wang P.S., Tsai Y., Liu H.S. Enterovirus 71-induced autophagy detected in vitro and in vivo promotes viral replication. J Med Virol. 2009;81(7):1241–1252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7166624</ArticleId><ArticleId IdType="pubmed">19475621</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao T., Li Y., Fan S., et al. Design, synthesis and pharmacological evaluation of a novel mTOR-targeted anti-EV71 agent. Eur J Med Chem. 2019;175:172–186.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082764</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y.Y., Li Y., Jiang W.Q., Zhou L.F. MAPK/JNK signalling: a potential autophagy regulation pathway. Biosci Rep. 2015;35(3)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4613668</ArticleId><ArticleId IdType="pubmed">26182361</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Li K., Ma L., et al. Berberine inhibits enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy. Virol J. 2017;14(1):2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5234143</ArticleId><ArticleId IdType="pubmed">28081706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.X., Yang L., Wang H.Q., et al. Synthesis and evolution of berberine derivatives as a new class of antiviral agents against enterovirus 71 through the MEK/ERK pathway and autophagy. Molecules. 2018;23(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6222558</ArticleId><ArticleId IdType="pubmed">30127288</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Guo T., Yang Y., Yu L., Pan X., Li Y. Lycorine derivative LY-55 inhibits EV71 and CVA16 replication through downregulating autophagy. Front Cell Infect Microbiol. 2019;9:277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692562</ArticleId><ArticleId IdType="pubmed">31448243</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Ning S., Su X., et al. Enterovirus 71 antagonizes the inhibition of the host intrinsic antiviral factor A3G. Nucleic Acids Res. 2018;46(21):11514–11527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6265463</ArticleId><ArticleId IdType="pubmed">30247716</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Zhong M., Li Y., et al. APOBEC3G is a restriction factor of EV71 and mediator of IMB-Z antiviral activity. Antiviral Res. 2019;165:23–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">30862444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y., Zheng Q., Wang Y., et al. Activity-based protein profiling identifies ATG4B as a key host factor for enterovirus 71 proliferation. J Virol. 2019;93(24)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6880168</ArticleId><ArticleId IdType="pubmed">31554687</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao Y., Yang Y., Hu D. Knockdown of METTL3 inhibits enterovirus 71-induced apoptosis of mouse Schwann cell through regulation of autophagy. Pathog Dis. 2021;79(6)</Citation><ArticleIdList><ArticleId IdType="pubmed">34279591</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu Y., Xu W., Chen D., et al. Enterovirus 71 induces autophagy by regulating has-miR-30a expression to promote viral replication. Antiviral Res. 2015;124:43–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">26515789</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris K.G., Coyne C.B. Death waits for no man–does it wait for a virus? How enteroviruses induce and control cell death. Cytokine Growth Factor Rev. 2014;25(5):587–596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371850</ArticleId><ArticleId IdType="pubmed">25172372</ArticleId></ArticleIdList></Reference><Reference><Citation>Song F., Yu X., Zhong T., et al. Caspase-3 inhibition attenuates the cytopathic effects of EV71 infection. Front Microbiol. 2018;9:817.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932146</ArticleId><ArticleId IdType="pubmed">29755438</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao C., Gao L., Wang C., Liu B., Jin Y., Xing Z. Structural characterization and antiviral activity of a novel heteropolysaccharide isolated from Grifola frondosa against enterovirus 71. Carbohydr Polym. 2016;144:382–389.</Citation><ArticleIdList><ArticleId IdType="pubmed">27083830</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin T.Y., Liu Y.C., Jheng J.R., et al. Anti-enterovirus 71 activity screening of chinese herbs with anti-infection and inflammation activities. Am J Chin Med. 2009;37(1):143–158.</Citation><ArticleIdList><ArticleId IdType="pubmed">19222118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsieh Y.J., Yen M.H., Chiang Y.W., et al. Gan-Lu-Siao-Du-yin, a prescription of traditional Chinese medicine, inhibited enterovirus 71 replication, translation, and virus-induced cell apoptosis. J Ethnopharmacol. 2016;185:132–139.</Citation><ArticleIdList><ArticleId IdType="pubmed">26993050</ArticleId></ArticleIdList></Reference><Reference><Citation>Song G., Ouyang G., Bao S. The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med. 2005;9(1):59–71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741304</ArticleId><ArticleId IdType="pubmed">15784165</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.H., Lee J., Jung Y.L., Hong A., Nam S.J., Lim B.K. Salvianolic acid B inhibits hand-foot-mouth disease enterovirus 71 replication through enhancement of AKT signaling pathway. J Microbiol Biotechnol. 2020;30(1):38–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9728356</ArticleId><ArticleId IdType="pubmed">31752055</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Wang W., Hao C., et al. Antiviral activity against enterovirus 71 of sulfated rhamnan isolated from the green alga Monostroma latissimum. Carbohydr Polym. 2018;200:43–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">30177184</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Wang W., Hou L., et al. A sulfated glucuronorhamnan from the green seaweed Monostroma nitidum: characteristics of its structure and antiviral activity. Carbohydr Polym. 2020;227</Citation><ArticleIdList><ArticleId IdType="pubmed">31590855</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo M., Zheng R., Wu H.L., et al. Inhibition of enterovirus 71 infection by polysaccharides extracted from Picochlorum sp. 122 via the AKT and ATM/ATR signaling pathways. Arch Virol. 2021</Citation><ArticleIdList><ArticleId IdType="pubmed">34536128</ArticleId></ArticleIdList></Reference><Reference><Citation>Du N., Li X.H., Bao W.G., Wang B., Xu G., Wang F. Resveratrol-loaded nanoparticles inhibit enterovirus 71 replication through the oxidative stress-mediated ERS/autophagy pathway. Int J Mol Med. 2019;44(2):737–749.</Citation><ArticleIdList><ArticleId IdType="pubmed">31173159</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhong J., Xia Y., Hua L., et al. Functionalized selenium nanoparticles enhance the anti-EV71 activity of oseltamivir in human astrocytoma cell model. Artif Cells Nanomed Biotechnol. 2019;47(1):3485–3491.</Citation><ArticleIdList><ArticleId IdType="pubmed">31422717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tung W.H., Hsieh H.L., Lee I.T., Yang C.M. Enterovirus 71 induces integrin β1/EGFR-Rac1-dependent oxidative stress in SK-N-SH cells: role of HO-1/CO in viral replication. J Cell Physiol. 2011;226(12):3316–3329.</Citation><ArticleIdList><ArticleId IdType="pubmed">21321939</ArticleId></ArticleIdList></Reference><Reference><Citation>You L., Chen J., Liu W., et al. Enterovirus 71 induces neural cell apoptosis and autophagy through promoting ACOX1 downregulation and ROS generation. Virulence. 2020;11(1):537–553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250321</ArticleId><ArticleId IdType="pubmed">32434419</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv X., Qiu M., Chen D., Zheng N., Jin Y., Wu Z. Apigenin inhibits enterovirus 71 replication through suppressing viral IRES activity and modulating cellular JNK pathway. Antiviral Res. 2014;109:30–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">24971492</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho H.Y., Cheng M.L., Weng S.F., Leu Y.L., Chiu D.T. Antiviral effect of epigallocatechin gallate on enterovirus 71. J Agric Food Chem. 2009;57(14):6140–6147.</Citation><ArticleIdList><ArticleId IdType="pubmed">19537794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Z., Ding Y., Cao L., Ding G., Wang Z., Xiao W. Isochlorogenic acid C prevents enterovirus 71 infection via modulating redox homeostasis of glutathione. Sci Rep. 2017;7(1):16278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5701158</ArticleId><ArticleId IdType="pubmed">29176678</ArticleId></ArticleIdList></Reference><Reference><Citation>Qing J., Wang Y., Sun Y., et al. Cyclophilin A associates with enterovirus-71 virus capsid and plays an essential role in viral infection as an uncoating regulator. PLoS Pathog. 2014;10(10):e1004422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4183573</ArticleId><ArticleId IdType="pubmed">25275585</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan W., Qing J., Mei H., et al. Identification, synthesis and pharmacological evaluation of novel anti-EV71 agents via cyclophilin A inhibition. Bioorg Med Chem Lett. 2015;25(24):5682–5686.</Citation><ArticleIdList><ArticleId IdType="pubmed">26564266</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., Shan J., Chen Z., et al. Chlorine dioxide inactivation of enterovirus 71 in water and its impact on genomic targets. Environ Sci Technol. 2013;47(9):4590–4597.</Citation><ArticleIdList><ArticleId IdType="pubmed">23560857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.C., Wu S.C. Effects of ozone exposure on inactivation of intra- and extracellular enterovirus 71. Antiviral Res. 2006;70(3):147–153.</Citation><ArticleIdList><ArticleId IdType="pubmed">16838411</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong T.W., Huang H.J., Wang Y.F., Lee Y.P., Huang C.C., Yu C.K. Methylene blue-mediated photodynamic inactivation as a novel disinfectant of enterovirus 71. J Antimicrob Chemother. 2010;65(10):2176–2182.</Citation><ArticleIdList><ArticleId IdType="pubmed">20719762</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadurugamuwa J.L., Shaheen E. Inactivation of human enterovirus 71 and coxsackie virus A16 and hand, foot, and mouth disease. Am J Infect Control. 2011;39(9):788–789.</Citation><ArticleIdList><ArticleId IdType="pubmed">21565426</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J, Li D, Xie G, et al.[Inactivation of EV71 by Exposure to Heat and Ultraviolet Light]. Bing Du Xue Bao. 2015;31(5):500–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian H., Yang Q.Z., Liang J., Dong S.Y., Liu Z.J., Wang L.X. Clinical features and management outcomes of severe hand, foot and mouth disease. Med Princ Pract. 2012;21(4):355–359.</Citation><ArticleIdList><ArticleId IdType="pubmed">22188681</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascual-Goñi E., Josa M., Launes C., et al. Excellent response to plasma exchange in three patients with enterovirus-71 neurological disease. Front Neurol. 2019;10:548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6542981</ArticleId><ArticleId IdType="pubmed">31178823</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson D.E., Cui J., Ye Q., Huang B., Tan Y., Jiang C., et al. Orthogonal genome-wide screens of bat cells identify MTHFD1 as a target of broad antiviral therapy. Proc Natl Acad Sci U S A. 2021;118(39)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488669</ArticleId><ArticleId IdType="pubmed">34544865</ArticleId></ArticleIdList></Reference><Reference><Citation>Martikainen M., Salorinne K., Lahtinen T., Malola S., Permi P., Häkkinen H., et al. Hydrophobic pocket targeting probes for enteroviruses. Nanoscale. 2015;7(41):17457–17467.</Citation><ArticleIdList><ArticleId IdType="pubmed">26440968</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakata K., Takeda S., Tanaka A., Kwang J., Komano J. Antiviral activity of acid beta-glucosidase 1 on enterovirus 71, a causative agent of hand, foot and mouth disease. J Gen Virol. 2017;98(4):643–651.</Citation><ArticleIdList><ArticleId IdType="pubmed">28141506</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura Y., Wakita T., Shimizu H. Tyrosine sulfation of the amino terminus of PSGL-1 is critical for enterovirus 71 infection. PLoS Pathog. 2010;6(11):e1001174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2973824</ArticleId><ArticleId IdType="pubmed">21079683</ArticleId></ArticleIdList></Reference><Reference><Citation>Chern J.H., Chang C.S., Tai C.L., et al. Synthesis and antipicornavirus activity of (R)- and (S)-1-[5-(4'-chlorobiphenyl-4-yloxy)-3-methylpentyl]-3-pyridin-4-yl-imidazolidin-2-one. Bioorg Med Chem Lett. 2005;15(19):4206–4211.</Citation><ArticleIdList><ArticleId IdType="pubmed">16054357</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L., Lee H., Thibaut H.J., et al. Viral engagement with host receptors blocked by a novel class of tryptophan dendrimers that targets the 5-fold-axis of the enterovirus-A71 capsid. PLoS Pathog. 2019;15(5):e1007760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6590834</ArticleId><ArticleId IdType="pubmed">31071193</ArticleId></ArticleIdList></Reference><Reference><Citation>Rivero-Buceta E., Sun L., Martínez-Gualda B., et al. Optimization of a class of tryptophan dendrimers that inhibit HIV replication leads to a selective, specific, and low-nanomolar inhibitor of clinical isolates of enterovirus A71. Antimicrob Agents Chemother. 2016;60(8):5064–5067.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4958208</ArticleId><ArticleId IdType="pubmed">27246775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo K.K., Chang J.S., Wang K.C., Chiang L.C. Water extract of Glycyrrhiza uralensis inhibited enterovirus 71 in a human foreskin fibroblast cell line. Am J Chin Med. 2009;37(2):383–394.</Citation><ArticleIdList><ArticleId IdType="pubmed">19507280</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang J.S., Wang K.C., Chiang L.C. Sheng-Ma-Ge-Gen-tang inhibited enterovirus 71 infection in human foreskin fibroblast cell line. J Ethnopharmacol. 2008;119(1):104–108.</Citation><ArticleIdList><ArticleId IdType="pubmed">18601992</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen M.H., Huang C.I., Lee M.S., et al. Artemisia capillaris inhibited enterovirus 71-induced cell injury by preventing viral internalization. Kaohsiung J Med Sci. 2018;34(3):150–159.</Citation><ArticleIdList><ArticleId IdType="pubmed">29475462</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., Tao J., Yang X., et al. Antiviral effects of two Ganoderma lucidum triterpenoids against enterovirus 71 infection. Biochem Biophys Res Commun. 2014;449(3):307–312.</Citation><ArticleIdList><ArticleId IdType="pubmed">24845570</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Takebe Y., Wakita T., Shimizu H. A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection. J Gen Virol. 2010;91(Pt 11):2734–2744.</Citation><ArticleIdList><ArticleId IdType="pubmed">20660150</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>